BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 32741478)

  • 1. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.
    Fernandes S; Varlamov EV; McCartney S; Fleseriu M
    Endocrinol Metab Clin North Am; 2020 Sep; 49(3):387-399. PubMed ID: 32741478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management.
    Kotwal A
    Curr Opin Endocrinol Diabetes Obes; 2021 Aug; 28(4):427-434. PubMed ID: 34183541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer immunotherapy-associated hypophysitis.
    Castillero F; Castillo-Fernández O; Jiménez-Jiménez G; Fallas-Ramírez J; Peralta-Álvarez MP; Arrieta O
    Future Oncol; 2019 Sep; 15(27):3159-3169. PubMed ID: 31423850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
    Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A
    J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
    Chang LS; Barroso-Sousa R; Tolaney SM; Hodi FS; Kaiser UB; Min L
    Endocr Rev; 2019 Feb; 40(1):17-65. PubMed ID: 30184160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.
    Kanie K; Iguchi G; Bando H; Urai S; Shichi H; Fujita Y; Matsumoto R; Suda K; Yamamoto M; Fukuoka H; Ogawa W; Takahashi Y
    Cancer Immunol Immunother; 2021 Dec; 70(12):3669-3677. PubMed ID: 33977343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary and Ipilimumab-induced Hypophysitis: A Single-center Case Series.
    Atkins P; Ur E
    Endocr Res; 2020 Nov; 45(4):246-253. PubMed ID: 32892666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How we treat endocrine complications of immune checkpoint inhibitors.
    Paschou SA; Stefanaki K; Psaltopoulou T; Liontos M; Koutsoukos K; Zagouri F; Lambrinoudaki I; Dimopoulos MA
    ESMO Open; 2021 Feb; 6(1):100011. PubMed ID: 33399077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary Dysfunction: A Case Series of Immune Checkpoint Inhibitor-Related Hypophysitis in an Emergency Department.
    Miller AH; Brock P; Jim Yeung SC
    Ann Emerg Med; 2016 Aug; 68(2):249-50. PubMed ID: 27451306
    [No Abstract]   [Full Text] [Related]  

  • 10. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
    Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
    Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces.
    Deligiorgi MV; Liapi C; Trafalis DT
    Expert Opin Biol Ther; 2021 Aug; 21(8):1097-1120. PubMed ID: 33393372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians.
    Deligiorgi MV; Panayiotidis MI; Trafalis DT
    Immunotherapy; 2020 May; 12(7):481-510. PubMed ID: 32345074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors and endocrine side effects, a narrative review.
    Agrawal L; Bacal A; Jain S; Singh V; Emanuele N; Emanuele M; Meah F
    Postgrad Med; 2020 Mar; 132(2):206-214. PubMed ID: 31876444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine immune-related adverse effects of immune-checkpoint inhibitors.
    Trevisani V; Iughetti L; Lucaccioni L; Predieri B
    Expert Rev Endocrinol Metab; 2023; 18(5):441-451. PubMed ID: 37682107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy-Associated Hypophysitis under Anti-PD1: Two Case Reports.
    Shen X; Yang M; Xu H; Zhou H; Wang L; Ma J
    Endocr Metab Immune Disord Drug Targets; 2023; 23(7):996-1004. PubMed ID: 36503448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine sequelae of immune checkpoint inhibitors.
    Ntali G; Kassi E; Alevizaki M
    Hormones (Athens); 2017 Oct; 16(4):341-350. PubMed ID: 29518754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
    Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
    J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features.
    Esteves-Ferreira S; Rosinha P
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7925-7932. PubMed ID: 36869230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
    Thapi S; Leiter A; Galsky M; Gallagher EJ
    J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.
    Joshi MN; Whitelaw BC; Palomar MT; Wu Y; Carroll PV
    Clin Endocrinol (Oxf); 2016 Sep; 85(3):331-9. PubMed ID: 26998595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.